Across TCGA pan-cancer cohorts, LY6G5C Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated LY6G5C data layer compared with 23 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher LY6G5C Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LY6G5C expression acts as an unfavorable survival marker.

LIHC are the cancer types where LY6G5C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.144	0.688	.013	9	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: LY6G5C tumor-vs-normal RNA expression · all LY6G5C data types